Arbutus reports third quarter 2023 financial results and provides corporate update

Multiple data presentations upcoming at aasld – the liver meeting®, including preliminary data from phase 2a clinical trial combining imdusiran, our rnai therapeutic, with vtp-300, an hbv antigen-specific immunotherapy
ABUS Ratings Summary
ABUS Quant Ranking